Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Obesity
NCT02741518Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in obesity (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Adverse Event Frequency at 6 months. Started Apr 2017; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02741518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741518.